SMARCA4 and neoplasm: To aid this strategy, an advanced molecular profiling with analyses of differential gene expression and chromatin profiling can be employed to identify whether BRG1 or any other targeted proteins of interest predominantly support oncogenic or tumor-suppressing pathways.